

U.S.S.N. 09/445,865
Filed: February 11, 2000
AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

1-28 canceled.

¹/₂₉ (currently amended) A method of treating a human patient with a target tumor cell to be destroyed wherein the target tumor cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a cytotoxic drug by the action of NQO2 and an analogue of nicotinamide riboside (reduced) (NRH) ~~having formula I:~~ which can pass reducing equivalents to NQO2, wherein the prodrug is CB 1954, and wherein R¹ is the analogue of nicotinamide riboside (reduced) (NRH) is 1-(carboxamidomethyl) dihydronicotinamide selected from the group consisting of: substituted alkyl, including substitution by CONH₂, OH, halogen, CN and COOH; alkyl; aryl; substituted aryl; CONR^aR^b; where R^a and R^b are independently H, alkyl, or substituted alkyl, and R² and R³ are independently H, alkyl, or substituted alkyl and R⁴ is any of H, alkyl, substituted alkyl, halogen, CN, COOH, CONH₂, or OH.

30. canceled.

¹/_{2 31} (previously presented) The method of claim ¹/₂₉ wherein the analogue of NRH is able to permeate the target cell membrane.

32. (canceled) The method of claim 29 wherein the target cell is a tumour.

³/₃₃ (currently amended) The method of claim ¹/₂₉, the method further comprising determining, before administering the prodrug and analogue of NRH, whether the target tumor cell to be treated expresses NQO2.

U.S.S.N. 09/445,865
Filed: February 11, 2000
AMENDMENT AND RESPONSE TO OFFICE ACTION

34-39 canceled.

40. (canceled) The method of claim 29 wherein the patient has cancer.

41-44 canceled.

OK
to enter

GW 01/05/04